Home › Phases › Preclinical

Preclinical (110 companies)

Companies with at least one active program at Preclinical.

Ticker	Company	Therapeutic areas	Preclinical programs	Lead stage	Programs
FDMT	4D Molecular Therapeutics	OphthalmologyRespiratory Rare	2	Phase 3	5
ABSI	Absci	DermatologyGI/Hepatology+1	3	Phase 1	6
ACRS	Aclaris Therapeutics	DermatologyGI/Hepatology+1 Rare	1	Phase 2	8
ACRV	Acrivon Therapeutics	Oncology	1	Phase 2	6
ACTU	Actuate Therapeutics	Oncology	1	Phase 2	4
ABOS	Acumen Pharmaceuticals	Neurology	2	Phase 2	4
ADAG	Adagene	Oncology	3	Phase 2	10
ADCT	ADC Therapeutics	Oncology	1	Approved	5
ACET	Adicet Bio	ImmunologyNeurology+2 Rare	1	Phase 1	8
ADMA	Adma Biologics	ImmunologyInfectious Disease Rare	1	Approved	4
AGMB	Agomab Therapeutics	ImmunologyRespiratory Rare	2	Phase 2	4
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	5	Approved	10
ALDX	Aldeyra Therapeutics	DermatologyOncology+1 Rare	2	NDA Submitted	7
ATHE	Alterity Therapeutics	Neurology Rare	1	Phase 2	2
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	1	Phase 3	5
ANIX	Anixa Biosciences	Oncology	1	Phase 1	3
APGE	Apogee Therapeutics	DermatologyGI/Hepatology+1 Rare	2	Phase 2	9
APVO	Aptevo Therapeutics	Oncology	6	Phase 1	8
RCUS	Arcus Biosciences	DermatologyImmunology+1	2	Phase 3	6
ARDX	Ardelyx	GI/HepatologyRenal	1	Approved	4
ARVN	Arvinas	NeurologyOncology Rare	2	Approved	12
ATAI	Atai Beckley	Neurology	2	Phase 2	5
BLTE	Belite Bio	MetabolicOphthalmology Rare	4	NDA Submitted	6
BMEA	Biomea Fusion	MetabolicOncology	1	Phase 2	4
BCTX	BriaCell Therapeutics	Oncology	5	Phase 3	7
CRDL	Cardiol Therapeutics	Cardiovascular Rare	1	Phase 3	4
CLRB	Cellectar Biosciences	Oncology	1	Phase 2	6
IPSC	Century Therapeutics	ImmunologyMetabolic+1 Rare	5	Phase 1	9
COGT	Cogent Biosciences	HematologyOncology Rare	1	NDA Submitted	7
CBIO	Crescent Biopharma	Oncology	1	Phase 2	10
CUE	Cue Biopharma	ImmunologyOncology	3	Phase 2	6
CGEM	Cullinan Therapeutics	HematologyImmunology+2 Rare	2	NDA Submitted	10
CTMX	CytomX Therapeutics	Oncology	1	Phase 1	6
DYN	Dyne Therapeutics	MetabolicNeurology Rare	8	NDA Submitted	10
EIKN	Eikon Therapeutics	Oncology	1	Phase 2	13
ELTX	Elicio Therapeutics	Oncology	3	Phase 2	6
ELOX	Eloxx Pharmaceuticals	DermatologyRenal Rare	1	Phase 2	4
ENTA	Enanta Pharmaceuticals	DermatologyImmunology+1	1	Phase 2	6
ENTX	Entera Bio	GI/HepatologyMetabolic Rare	2	Phase 2	4
ERAS	Erasca	Oncology	1	Phase 1	3
ETON	Eton Pharmaceuticals	GI/HepatologyInfectious Disease+2 Rare	1	Approved	14
EXEL	Exelixis	CardiovascularOncology	1	Approved	22
EYPT	EyePoint	Ophthalmology	1	Phase 3	3
FHTX	Foghorn Therapeutics	Oncology	3	Phase 1	5
FBIO	Fortress Biotech	DermatologyHematology+2 Rare	1	Approved	12
GUTS	Fractyl Health	Metabolic	2	Phase 3	3
GANX	Gain Therapeutics	MetabolicNeurology Rare	4	Phase 1	5
IMUX	Immunic	GI/HepatologyNeurology	1	Phase 3	4
IMNM	Immunome	Oncology Rare	2	NDA Submitted	9
INAB	IN8bio	ImmunologyOncology	3	Phase 2	6
INSM	Insmed	CardiovascularDermatology+2 Rare	1	Approved	9
JBIO	Jade Biosciences	ImmunologyRenal Rare	2	Phase 2	4
KAPA	Kairos Pharma	Oncology	7	Phase 2	9
KOD	Kodiak Sciences	Ophthalmology	2	Phase 3	8
KURA	Kura Oncology	MetabolicOncology	3	Approved	12
KYTX	Kyverna Therapeutics	ImmunologyNeurology+1 Rare	1	NDA Submitted	7
LXEO	Lexeo Therapeutics	CardiovascularNeurology Rare	4	Phase 1	8
LCTX	Lineage Cell Therapeutics	NeurologyOphthalmology Rare	3	Phase 2	5
LGVN	Longeveron	CardiovascularMetabolic+1 Rare	1	Phase 2	4
MAIA	MAIA Biotechnology	Oncology	6	Phase 3	7
MPLT	MapLight Therapeutics	Neurology	3	Phase 2	6
MRKR	Marker Therapeutics	Oncology	1	Phase 1	4
MDNAF	Medicenna Therapeutics	Oncology	6	Phase 2	9
INKT	MiNK Therapeutics	ImmunologyOncology+1 Rare	3	Phase 2	7
GLUE	Monte Rosa Therapeutics	CardiovascularDermatology+2 Rare	1	Phase 2	6
NKTR	Nektar Therapeutics	DermatologyImmunology+2	4	Phase 3	11
NGEN	NervGen Pharma	Neurology	2	Phase 1	3
NRSN	NeuroSense Therapeutics	Neurology Rare	1	Phase 2	3
NRXP	NRX Pharmaceuticals	Neurology	2	NDA Submitted	5
NRIX	Nurix Therapeutics	ImmunologyNeurology+1	1	Phase 3	16
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	3	Phase 3	12
OCS	Oculis Holding	NeurologyOphthalmology Rare	1	Phase 3	4
OMER	Omeros	HematologyNeurology+2 Rare	2	Approved	6
IRD	Opus Genetics	Ophthalmology Rare	5	Approved	14
ORKA	Oruka Therapeutics	DermatologyImmunology Rare	1	Phase 2	7
OVID	Ovid Therapeutics	Neurology Rare	2	Phase 2	4
PALI	Palisade Bio	Immunology	1	Phase 1	3
KTTA	Pasithea Therapeutics	NeurologyOncology Rare	2	Phase 1	4
PHIO	Phio Pharmaceuticals	Oncology	1	Phase 1	4
PYPD	PolyPid	Infectious DiseaseOncology	1	NDA Submitted	2
DTIL	Precision Biosciences	Infectious DiseaseMetabolic+1 Rare	1	Phase 1	5
PCSA	Processa Pharmaceuticals	GI/HepatologyImmunology+2 Rare	3	Phase 2	7
PMN	ProMIS Neurosciences	Neurology Rare	5	Phase 1	6
QNRX	Quoin Pharmaceuticals	DermatologyImmunology Rare	2	Phase 2	4
RLMD	Relmada Therapeutics	MetabolicNeurology+1 Rare	1	Phase 2	4
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	4	Phase 3	10
SANA	Sana Biotechnology	MetabolicOncology	3	Phase 1	4
SRPT	Sarepta Therapeutics	NeurologyRespiratory Rare	1	Approved	10
SCYX	Scynexis	Infectious DiseaseRenal Rare	1	Approved	5
SLS	SELLAS Life Sciences Group	Oncology	3	Phase 3	9
SLDB	Solid Biosciences	CardiovascularNeurology Rare	3	Phase 3	6
SPRB	Spruce Biosciences	Metabolic Rare	1	Preclinical	2
SYRE	Spyre Therapeutics	DermatologyImmunology Rare	1	Phase 2	13
GPCR	Structure Therapeutics	MetabolicRespiratory Rare	1	Phase 3	5
STRO	Sutro Biopharma	Oncology	3	Phase 1	4
TSHA	Taysha Gene Therapies	Neurology Rare	2	Phase 3	4
TVTX	Travere Therapeutics	MetabolicRenal Rare	2	Approved	7
TTRX	Turn Therapeutics	DermatologyInfectious Disease Rare	2	Phase 2	4
RARE	Ultragenyx Pharmaceutical	CardiovascularGI/Hepatology+2 Rare	1	Approved	12
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	1	Approved	29
PCVX	Vaxcyte	Infectious Disease	2	Phase 3	6
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	1	Approved	6
VIR	Vir Biotechnology	Infectious DiseaseOncology Rare	1	Phase 3	10
VRDN	Viridian Therapeutics	ImmunologyOphthalmology	1	Approved	5
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	8	Phase 1	9
VTVT	vTv Therapeutics	MetabolicRespiratory Rare	1	Phase 3	8
WVE	Wave Life Sciences	MetabolicNeurology+1 Rare	1	Phase 2	5
XENE	Xenon Pharmaceuticals	Neurology Rare	1	Phase 3	8
ZBIO	Zenas BioPharma	DermatologyImmunology+2 Rare	2	NDA Submitted	11
ZYME	Zymeworks	OncologyRespiratory	4	Approved	11